EQS-News: GeoVax to Sponsor the 2025 Dr. David Satcher Global Health Equity Summit

Company Underscores Its Commitment to Advancing Equitable Access to Vaccines and Health Innovation on a Global Stage

ATLANTA, GA - October 1, 2025 (NEWMEDIAWIRE) - GeoVax, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing multi-antigen vaccines and immunotherapies for infectious diseases and cancer, today announced its sponsorship of the 3rd Annual Dr. David Satcher Global Health Equity Summit, hosted by Morehouse School of Medicine. The summit will take place October 2, 2025, at Morehouse School of Medicine in Atlanta, Georgia. Summit details here.

Summit Theme: “The Quest for Health Equity & Justice: A Glocal Perspective”

The Dr. David Satcher Global Health Equity Summit convenes global health experts, policymakers, researchers, community organizations, and students to address pressing challenges in health equity. This year’s agenda will highlight how local (“glocal”) innovations, policies, and partnerships can be scaled globally to close equity gaps in access to healthcare.

The 2025 Summit will feature keynote speaker Dr. John N. Nkengasong, U.S. Global AIDS Coordinator and Senior Bureau Official for Global Health Security and Diplomacy, alongside distinguished leaders across academic, government, and private sectors. Sessions will explore topics such as vaccine access and trust, innovations in pandemic preparedness, and community-driven models for health equity.

GeoVax Participation

Representing GeoVax at the Summit will be Mary Hauser, PhD, Director of Preclinical Research, who will be available throughout the event to discuss the Company’s vaccine and immunotherapy programs. Dr. Hauser will highlight GeoVax’s work advancing MVA-based vaccines designed to meet the needs of immunocompromised and underserved populations, underscoring the Company’s commitment to ensuring that scientific innovation translates into real-world accessibility.

“Health equity is not just a goal - it is a mandate for global progress,” said David Dodd, Chairman & CEO of GeoVax. “We are honored to support the Satcher Summit and partner with Morehouse School of Medicine in advancing solutions that ensure lifesaving vaccines and therapies reach those most in need.”

About the Dr. David Satcher Global Health Equity Summit

Founded in honor of Dr. David Satcher, the 16th Surgeon General of the United States and Founding Director of the Satcher Health Leadership Institute, the annual summit provides a platform for advancing health equity through research, innovation, and policy. Now in its third year, the event serves as a catalyst for collaboration and action to achieve sustainable change in global and community health.

About GeoVax

GeoVax Labs, Inc. is a clinical-stage biotechnology company developing novel vaccines against infectious diseases and therapies for solid tumor cancers. The Company’s lead clinical program is GEO-CM04S1, a next-generation COVID-19 vaccine currently in three Phase 2 clinical trials, being evaluated as (1) a primary vaccine for immunocompromised patients such as those suffering from hematologic cancers and other patient populations for whom the current authorized COVID-19 vaccines are insufficient, (2) a booster vaccine in patients with chronic lymphocytic leukemia (CLL) and (3) a more robust, durable COVID-19 booster among healthy patients who previously received the mRNA vaccines. In oncology the lead clinical program is evaluating a novel oncolytic solid tumor gene-directed therapy, Gedeptin®, having recently completed a multicenter Phase 1/2 clinical trial for advanced head and neck cancers. GeoVax is also developing a vaccine targeting Mpox and smallpox and, based on recent EMA regulatory guidance, anticipates progressing directly to a Phase 3 clinical evaluation, omitting Phase 1 and Phase 2 trials. GeoVax has a strong IP portfolio in support of its technologies and product candidates, holding worldwide rights for its technologies and products. For more information about the current status of our clinical trials and other updates, visit our website: www.geovax.com.

Forward-Looking Statements

This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.

Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Company Contact:
info@geovax.com
678-384-7220

Media Contact:
Jessica Starman
media@geovax.com